Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 1999

View Archived Issues

Targretin overcomes tamoxifen resistance in preclinical testing

Aurora Biosciences announces two ion channel technology agreements

Protherics updates programs, announces collaboration with Lilly

Biomatrix files 510K submission for sinus surgery adhesion prevention device

Cambridge NeuroScience issued two patents, three patent allowances

Cytoclonal describes recent progress in telomerase production, inhibitors

Chinese investigators describe antimycoplasmal activity of new quinolone

Transgene presents phase II data for cancer vaccine

CeaVac trial reaches accrual goal; phase II trial will be expanded to phase III

Transkaryotic Therapies achieves milestone in Aventis collaboration

DSMB recommends continuation of Allovectin-7 trials

Spanish investigators disclose new diazaanthraquinones for malignant tumors

Recently issued patent covers Berlex's new anticoagulants

Urea derivatives from Santen inhibit TNF-alpha production

New oral carbapenems with activity against wide range of bacteria

Compounds active against RNA viruses emerge from research at Italian university

New use for sPLA2 inhibitor claimed by Lilly: LY-315920 for IBS

DA-125: well tolerated but not effective in phase II trial in NSCLC

Late January meeting of FDA advisory panel will review NDAs for ProMem and Novantrone

Acute effects of KA-672 on binding in mouse brain studied in vivo

Glaxo Wellcome seeks approval for new IBS treatment in the E.U.

PPD GenuPro retains rights to dapoxetine for treatment of premature ejaculation

Aronex to submit NDA amendment for Atragen in first half of 2000

Axonyx commences phase I clinical trial of phenserine

Vivus seeks FDA approval for new impotence drug

Genome Therapeutics achieves milestone in asthma genomics alliance with Schering-Plough

Organogenesis seeks FDA approval of Apligraf for diabetic foot ulcers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...